- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00066508
Bortezomib in Treating Patients With Diffuse Large B-Cell Lymphoma That Is Refractory To Chemotherapy
A Phase II Study Of PS-341 (VELCADE) In Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth.
PURPOSE: Phase II trial to study the effectiveness of bortezomib in treating patients who have diffuse large B-cell lymphoma that is refractory to previous chemotherapy.
Studieöversikt
Detaljerad beskrivning
OBJECTIVES:
- Determine the overall response rate in patients with chemotherapy-refractory diffuse large B-cell lymphoma treated with bortezomib.
- Determine the safety and tolerability of this drug in these patients.
- Determine the time to disease progression in patients treated with this drug.
- Determine the possible mechanism of resistance to this drug in these patients.
OUTLINE: This is an open-label, multicenter study.
Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
Patients are followed at 20 days and then every 3 months thereafter.
PROJECTED ACCRUAL: A total of 22-40 patients will be accrued for this study.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 2
Kontakter och platser
Studieorter
-
-
California
-
Los Angeles, California, Förenta staterna, 90095
- Jonsson Comprehensive Cancer Center at UCLA
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
DISEASE CHARACTERISTICS:
Histologically confirmed diffuse large B-cell lymphoma, meeting criteria for 1 of the following:
- Relapsed after prior high-dose chemotherapy with stem cell support
- Relapsed after prior chemotherapy, including at least 1 prior standard non-Hodgkin's chemotherapy regimen, but not a candidate for high-dose chemotherapy with stem cell support
Measurable disease
- At least 1 bidimensionally measurable lesion at least 1.5 cm by CT scan
- No primary or secondary CNS lymphoma
- No HIV-related lymphoma
- No known brain metastases
PATIENT CHARACTERISTICS:
Age
- 18 and over
Performance status
- ECOG 0-2 OR
- Karnofsky 60-100%
Life expectancy
- More than 3 months
Hematopoietic
- Hemoglobin at least 9 g/dL
Absolute neutrophil count at least 1,000/mm^3
- No colony-stimulating factors within 4 weeks before obtaining this result
Platelet count at least 50,000/mm^3
- No platelet transfusion within 4 weeks before obtaining this result
Hepatic
- Bilirubin no greater than 2 times upper limit of normal (ULN)
- AST and ALT no greater than 2.5 times ULN
- No active hepatitis B or C viral infection
Renal
- Creatinine no greater than 2 times ULN OR
- Creatinine clearance at least 60 mL/min
Cardiovascular
- No myocardial infarction within the past 6 months
- No evidence of acute ischemia or new conduction system abnormalities on EKG
- No symptomatic congestive heart failure
- No unstable angina pectoris
- No cardiac arrhythmia
Other
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- Sodium greater than 130 mEq/L
- HIV negative
- No ongoing or active infection
- No other concurrent uncontrolled illness that would preclude study participation
- No psychiatric illness or social situation that would preclude study compliance
- No prior allergic reaction attributable to compounds of similar chemical or biological composition to bortezomib
PRIOR CONCURRENT THERAPY:
Biologic therapy
- See Disease Characteristics
- See Chemotherapy
- At least 4 weeks since prior immunotherapy
Chemotherapy
- See Disease Characteristics
- More than 4 weeks since prior chemotherapy
- More than 12 weeks since prior high-dose chemotherapy with hematopoietic stem cell support
Endocrine therapy
- Not specified
Radiotherapy
- More than 4 weeks since prior radiotherapy
- No concurrent radiotherapy
Surgery
- More than 4 weeks since prior major surgery unless fully recovered
Other
- Recovered from prior therapy
- No other concurrent investigational agents
- No other concurrent investigational or commercial agents or therapies to treat the malignancy
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Maskning: Ingen (Open Label)
Vad mäter studien?
Primära resultatmått
Resultatmått |
---|
Overall response rate (combined complete response and partial response)
|
Sekundära resultatmått
Resultatmått |
---|
Dags för sjukdomsprogression
|
Säkerhet
|
Tolerabilitet
|
Possible mechanism of resistance
|
Samarbetspartners och utredare
Samarbetspartners
Utredare
- Studiestol: Sven De Vos, MD, Jonsson Comprehensive Cancer Center
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- CDR0000316254
- UCLA-0301090
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på bortezomib
-
The First Affiliated Hospital of Soochow UniversityOkändMultipelt myelom bevisat genom laboratorietesterKina
-
Baylor College of MedicineMillennium Pharmaceuticals, Inc.AvslutadProstata neoplasmerFörenta staterna
-
NCIC Clinical Trials GroupAvslutad
-
University Hospital, Clermont-FerrandLaboratoires TakedaOkändMultipelt myelom | Vuxen | Bortezomib-regimenFrankrike
-
National Cancer Institute (NCI)AvslutadMag-tarmcancer | Avancerad primär vuxen levercancer | Lokaliserad ooperbar primär levercancer hos vuxna | Återkommande vuxen primär levercancer | Återkommande extrahepatisk gallvägscancer | Återkommande cancer i gallblåsan | Ooperbar extrahepatisk gallvägscancer | Inoperabel gallblåscancer | Adenocarcinom... och andra villkorFörenta staterna
-
Janssen-Cilag International NVAvslutadMultipelt myelomKalkon, Grekland, Tjeckien, Österrike, Tyskland, Sverige, Storbritannien, Danmark
-
University Health Network, TorontoNational Cancer Institute (NCI)AvslutadBlåscancer | Övergångscellscancer i njurbäckenet och urinledarenFörenta staterna, Kanada
-
Janssen Korea, Ltd., KoreaAvslutad
-
Southwest Oncology GroupNational Cancer Institute (NCI)Avslutad
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)AvslutadLymfom | Myelodysplastiska syndrom | Leukemi | Multipelt myelom och plasmacellsneoplasmaFörenta staterna